Purple Biotech (PPBT) Income towards Parent Company (2014 - 2026)
Purple Biotech's (PPBT) quarterly Income towards Parent Company came in at $86000.0 in Q1 2026, down 81.02% year-on-year from $453000.0 in Q1 2025, and down 99.63% on a QoQ basis from $23.5 million in Q4 2025.
Purple Biotech (PPBT) Income towards Parent Company (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 13 years of Income towards Parent Company data on file, last reported at $86000.0 in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 81.02% year-over-year to $86000.0 in Q1 2026; TTM through Mar 2026 was $26.0 million, a 560.91% increase from a year earlier, with the FY2025 full-year figure at -$26.4 million, down 264.45% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $86000.0, down from $23.5 million in the prior quarter.
- Over the last five years, Income towards Parent Company for PPBT reached as high as $23.5 million in Q4 2025 and fell as low as $86000.0 in Q1 2026.
- Historically, Income towards Parent Company has averaged $4.4 million across 5 years, with a median of $3.8 million in 2024.
- Across the five-year window, Income towards Parent Company plunged 91.51% in 2024 and surged 5642.93% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $6.0 million in 2022, then slipped by 19.68% to $4.8 million in 2023, then plunged by 91.51% to $410000.0 in 2024, then jumped by 5642.93% to $23.5 million in 2025, then sank by 99.63% to $86000.0 in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $86000.0 in Q1 2026, $23.5 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Purple Biotech | 1.35 Bn | 1.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 23.55 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 453,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 663,000.00 |
| Jun 30, 2024 | 2.41 Mn |
| Mar 31, 2024 | 3.78 Mn |
| Dec 31, 2023 | 4.83 Mn |
| Sep 30, 2023 | 5.04 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 3.56 Mn |
| Mar 31, 2022 | 7.30 Mn |
| Dec 31, 2021 | 8.21 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 3.63 Mn |